Biological and Pharmaceutical Bulletin
Online ISSN : 1347-5215
Print ISSN : 0918-6158
ISSN-L : 0918-6158
The Novel Thromboxane A2 Receptor Antagonist KW-3635 Abolishes the Cyclic Flow Reduction in the Canine Carotid Artery
Katsuya HIGOAkira KARASAWA
Author information
JOURNALS FREE ACCESS

1994 Volume 17 Issue 7 Pages 902-906

Details
Abstract

We tested the hypothesis that the abolition of the cyclic flow reduction (CFR) in the canine carotid artery is related to inhibition of ex vivo platelet aggregation following administration of KW-3635, a thromoxane A2 receptor antagonist, or aspirin. The CFR was induced in the carotid artery of anesthetized dogs by mechanical injury and narrowing of the artery. After induction of CFR, KW-3635 or aspirin was administered every 30 min at doses of 0, 1, 0.3, 1 and 3 mg/kg (i.v.). The ex vivo platelet aggregation, induced by sodium arachidonate and collagen, was also examined before and 15 min after each administration. KW-3635 and aspirin, at doses of 1 mg/kg i.v. and above, inhibited CFR and ex vivo platelet aggregation. These results suggest that CFR in the canine carotid artery is platelet-dependent.

Information related to the author
© The Pharmaceutical Society of Japan
Previous article Next article
feedback
Top